mRNA therapy for pulmonary edema
Pulmonary edema / vascular barrier dysfunction
Pre-clinicalActive
Key Facts
Indication
Pulmonary edema / vascular barrier dysfunction
Phase
Pre-clinical
Status
Active
Company
About Pantherna Therapeutics
Pantherna Therapeutics is a private, pre-clinical stage biotech focused on overcoming a key limitation in mRNA therapeutics: delivery beyond the liver. The company's proprietary platform, built on its PTXmRNA™ and PTXΔLNP™ technologies, aims to enable tissue-specific targeting, with an initial lead program targeting pulmonary edema. Leveraging public funding and open to partnerships, Pantherna is positioning itself in the competitive next-generation LNP space to expand the reach of mRNA therapies.
View full company profile